imtoken钱包下载2.0|bsx

作者: imtoken钱包下载2.0
2024-03-07 17:33:13

波士顿科学(BSX)股票股价_股价行情_财报_数据报告 - 雪球

学(BSX)股票股价_股价行情_财报_数据报告 - 雪球首页行情行情中心筛选器新股上市买什么交易A股交易基金交易私募中心下载App扫一扫,下载登录/注册公司概况公司简介公司高管内部持股所属指数股票交易盘前交易盘后交易历史价格期权交易空仓数据内部交易市场预期财报公告SEC文件财报公告(中)财报公告(英)电话会议实录财务数据主要指标分红派息利润表资产负债表现金流量表雪球选股器研究分析收益预估评级变化研究报告APP专享大盘异动股价提醒购买指数相关ETF扫码下载雪球App查看详情波士顿科学(NYSE:BSX)可融资可卖空$67.42+0.40 +0.60% 4181 球友关注盘前交易 03-06 16:10:00 美东时间最高:67.44今开:67.10成交量:640.10万股换手:0.44%最低:66.84昨收:67.02成交额:4.30亿振幅:0.89%52周最高:67.67量比:0.90市盈率(TTM):62.17市净率:5.1352周最低:46.20委比:-33.33%市盈率(静):62.17市销率:6.95每股收益:1.08股息(TTM):--每手股数:1总市值:989.12亿每股净资产:13.16股息率(TTM):--最小价差:0.01总股本:14.67亿机构持股:--Beta:--空头回补天数:--货币单位:USD分时五日日K周K月K季K年K120分60分30分15分5分1分区间统计全屏显示股票对比前复权前复权后复权不复权MABOLL成交量MACDKDJPEPSPCF总市值WRRSIBIASCCIPSY近1月近3月近6月近1年近3年近5年今年以来上市以来-简介波士顿科学国际有限公司的历史始于1960年代后期。该公司是医疗器械的全球开发商,制造商和销售商,这些医疗器械被广泛用于介入性医疗专业。该公司的内窥镜业务开发和制造用于诊断和治疗侵入性和微创技术的设备,以诊断和治疗广泛的胃肠道和肺部疾病。泌尿外科和盆腔健康业务开发和制造用于治疗各种泌尿和盆腔疾病的设备男性和女性解剖结构,包括肾结石,良性前列腺增生(BPH),前列腺癌,勃起功能障碍,失禁,骨盆底障碍,异常子宫出血以及子宫肌瘤和息肉。该公司的心律管理(CRM)业务开发和制造各种植入式设备,这些设备可监测心脏并输送电力以治疗心脏异常。该公司的电生理业务开发和制造用于诊断和治疗心脏的速率和节律紊乱的微创医疗技术,包括广泛的治疗和诊断导管产品以及电生理实验室中使用的各种设备。该公司的Neuromodulation业务开发和制造用于治疗各种神经系统运动障碍和管理慢性疼痛的设备。该公司的介入心脏病学业务开发,制造和商业化用于诊断和治疗冠状动脉疾病和其他心血管疾病(包括结构性心脏病)的技术。公司网站:http://www.bostonscientific.com公司地址:300 Boston Scientific Way

Marlborough

MA 01752-1234公司电话:1-508-6834000收起波士顿科学国际有限公司的历史始于1960年代后期。该公司是医疗器械的全球开发商,制造商和销售商,这些医疗器械被广泛用于介入性医疗专...展开业务医疗器械的制造和销售

波士顿科学(BSX)股票股价,实时行情,新闻,财报,研报评级_新浪财经_新浪网

波士顿科学(BSX)股票股价,实时行情,新闻,财报,研报评级_新浪财经_新浪网

财经首页 | 新浪首页 | 新浪导航

财经首页

美股首页

滚动

评论

美股列表

中国概念股

美股行情中心

美股自选

退出

您好! 请登录

北京DD日 H:M:S | 美东DD日 H:M:S

新浪财经 > 行情中心 > 美股 >

医疗保健产品 >

波士顿科学

行情

新闻

中概股财报

BSX导航

行情

该浏览器不支持Flash版行情。

HTML5版行情

HTML5版行情支持火狐、谷歌等最新版本浏览器。

图片版行情

历史价格

期权

空仓

股价提醒

新闻资讯

公司新闻

公司研究

SEC Filings

电话会议

中概股财报

股东

主要股东

内部人交易

财务

资产负债表

利润表

现金流量表

分红派息

相关信息

公司简介

高管

董事会

医疗保健产品行业

中国概念股

波士顿科学 NYSE:BSX

Boston Scientific Co

添加自选

在APP中查看

普通版

极速版

盘后 :

@hourTradingPrice@ @hourTradingChange@(@hourTradingChangeP@%)

成交量:@hourTradingVolume@

@hourTradingDateTime@

使用极速版请先登录登录,极速版行情更新速度比标准版快若干倍。为达到更好的体验,建议使用火狐、谷歌等最新版本浏览器。

详细行情

基本面摘要

开盘:

@open@

前收盘:

@preClose@

市盈率:

@pe@

市值:

@totalShare@

成交量:

@volume@

区间:

@low@-@high@

每股收益:

@eps@

股本:

@shares@

10日均量:

@averageVolume@

52周区间:

@low52@-@high52@

贝塔系数:

@beta@

股息/收益率:

@dividend@/@income@

行情对比:

大盘指数

纳斯达克

道琼斯

标普500

当日

5日

日K

周K

月K

当日

5日

收盘线

日K

周K

月K

YTD

5分

15分

30分

最近访问股

自选股

名称

最新价

涨跌幅

以下为热门股票

查看自选股请先

登录

名称

最新价

涨跌幅

添加股票

公司资讯

(03-05 12:17)波士顿科学公司AGEN球囊导管获批,助力冠心病患者抗击再狭窄(03-04 19:58)波士顿科学AGENT药物涂层球囊导管获FDA批准(02-29 11:28)进博故事丨国际罕见病日:“四叶草”里成长的“进博宝宝”(02-29 07:36)C3.ai(AI.US)盘后涨超13%!Q3业绩超预期 上调全年营收指引(02-29 07:36)C3.ai盘后涨超13%!Q3业绩超预期 上调全年营收指引(02-25 13:48)158亿!波士顿科学(BSX.US)有大动作!(02-14 07:45)裁员潮已来?年初医疗械企裁员大盘点(02-12 17:24)继Meta史上首度分红后 下一家会是谁?

(03-07 17:15)

日元兑美元涨1% 薪资数据强于预期促使市场押注

(03-07 17:11)

美股中概股盘前普跌 达达集团跌超7%

(03-07 17:04)

诺和诺德盘前涨3.5% 将举行活动介绍Wego

(03-07 16:58)

SK海力士今年将投资10亿美元发展高带宽内存技

(03-07 16:57)

韩国比特币散户投资者正在回归,“泡菜溢价”创两

(03-07 16:53)

摩根大通:首予华住“增持”评级 目标价40美元

(03-07 16:48)

裕信银行:若欧央行预测经济大幅下滑,欧元高收益

(03-07 16:44)

大摩:美元将在年底走强,不看好短期内升值

更多

(02-03 21:19)FDA批准波士顿科学的FARAPULSE PFA系统,为反复发作的症状性房颤提供新的治疗选择(01-31 22:33)波士顿科学(BSX.N)涨3.3%,四季度净利润超过预期,且指引乐观。(01-25 14:10)中国发展战略提档升级,波士顿科学连获三项大奖认可(01-17 06:05)波士顿科学(BSX.US)Fitzgerald Joseph Michael售出1.17万股普通股股份,价值约69.96万美元(01-16 07:10)投行Baird看好2024年医疗技术股跑赢大盘,首选爱尔康和波士顿科学等公司(01-11 11:03)波士顿科学公司收购Axonics,拓展泌尿产品组合(01-10 14:57)波士顿科学宣布达成协议以每股71美元收购医疗技术公司Axonics(01-03 09:55)波士顿科学(BSX.US)Fitzgerald Joseph Michael售出8.19万股普通股股份,价值约471.16万美元

展开网友评论

收起网友评论

多空看板

买入

增持

持有

减持

卖出

网友评论

您好,

您好,发言请先进行微博授权

已有534条评论,共有459人参与

还可以输入137个字符

到 微博 查看您的发言

更多...

可能感兴趣的人

换一换

认证微博

关注BSX的好友

(@num@)

上一页 下一页

关注BSX的还关注

名称

最新价

涨跌幅

更多网友正在看

名称

最新价

涨跌幅

正在查看当前页的好友

美股行情(含NASDAQ、NYSE、AMEX)为实时行情,由纳斯达克提供。沪深股市、港股、外汇、黄金、原油等行情均为实时行情;其他市场指数行情至少延时15分钟。新浪财经免费提供的行情数据以及其他资料均来自合作方,仅作为用户获取信息之目的,并不构成投资建议。新浪财经以及其合作机构不为本页面提供的信息错误、残缺、延时或因依靠此信息所采取的任何行动负责。市场有风险,投资需谨慎。

客户服务热线:4000520066  

欢迎批评指正

常见问题解答

互联网违法和不良信息举报 

新浪财经意见反馈留言板

新浪简介 | About Sina | 广告服务 | 联系我们 | 招聘信息 | 网站律师 | SINA English | 通行证注册 | 产品答疑新浪公司 版权所有

新浪财经免费提供股票、基金、债券、外汇等行情数据以及其他资料均来自相关合作方,仅作为用户获取信息之目的,并不构成投资建议。新浪财经以及其合作机构不为本页面提供信息的错误、残缺、延迟或因依靠此信息所采取的任何行动负责。市场有风险,投资需谨慎。

用户名:

密  码:

记录登录状态一个月

登录

找回密码

登录帮助

还不是新浪会员?

新用户注册

×

Boston Scientific | Advancing Science For Life

Boston Scientific | Advancing Science For Life

skip to main content

News

Careers

Investors Home

Home

Contact Us

Open SearchSearch

CloseClose Search

CloseClose Search

Login or register image icon

Login

Register

Social media sharing image icon

Share on Twitter

Share on Facebook

Share on LinkedIn

Email this page

MenuClose Hamburger menu

Investors Home

Business OverviewEventsFinancials & Filings

Quarterly Results & Non-GAAP ReconciliationsAnnual Results & Proxy StatementsSEC Filings

FundamentalsStock

Stock Quote & ChartHistorical Price LookupInvestment CalculatorStock Split HistorySell Side Analyst Coverage

ESG

Corporate ResponsibilityGovernance OverviewBoard of Directors

Resources

Email AlertsInvestor FAQsContact InformationTransfer Agent Contact Information

NewsCareers

Click here for Documents / Information related to Offer to Acquire BTG plc.

Business OverviewEventsFinancials & Filings

Quarterly Results & Non-GAAP ReconciliationsAnnual Results & Proxy StatementsSEC Filings

FundamentalsStock

Stock Quote & ChartHistorical Price LookupInvestment CalculatorStock Split HistorySell Side Analyst Coverage

ESG

Corporate ResponsibilityGovernance OverviewBoard of Directors

Resources

Email AlertsInvestor FAQsContact InformationTransfer Agent Contact Information

NewsCareers

Main Content

Investors

$14.2

billion FY 2023 sales

$2.05

adjusted EPS1 in 2023

$2.5

billion adjusted free cash flow1 in 2023

Q4 2023

Recent Quarterly Results

Q4 2023 Earnings Release and Financial Results

Q4 2023 Financial and Operational Highlights

Go to Q4 2023

Events

There are currently no events scheduled.

Go to Events

Reports & Filings

Annual Results and Proxy Statements

2022 Annual Report and Form 10-K

2023 Proxy Statement

2022 Performance Report

Go to Reports & Filings

Business Overview

Presentations

2023 Investor Day

2023 J.P. Morgan Healthcare Conference

ESG Resources

Environmental, Social, and Corporate Governance

Governance Overview

Board of Directors

Go to ESG Resources

Go to Stock Quote & Chart page

1 Non-GAAP measure; excludes certain GAAP items. For reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to our Financial Disclaimers and Non-GAAP Reconciliations.

Safe Harbor for forward-looking statements

This site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Connect with Boston Scientific Investor Relations

Investor relations contact

300 Boston Scientific WayMailstop M405Marlborough, MA 01752BSXInvestorRelations@bsci.com

Quick Links

Investor FAQs

Contact Information

Email Alerts

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

Follow on Twitter Follow on Facebook Follow on LinkedIn Follow the rss feed

©2024

Boston Scientific Corporation or its affiliates. All rights reserved.

Privacy Policy Terms of Use Copyright Notice Site Map

Do not sell or share my personal information

BSX Stock Price Quote | Morningstar

BSX Stock Price Quote | Morningstar

Skip to Content

Morningstar brands and products

Company

Get 7 Days Free

Sign In

Sign In

Topics Investing Ideas MarketsStocksFundsETFsBondsPortfolio

Markets

Stocks

Funds

ETFs

Bonds

Investing Ideas

Best Investments

Christine Benz’s Portfolios

Best Companies to Own

Best ETFs

Guide to 529 Plans

Asset Management Companies

Topics

Portfolio Construction

Economy

Sustainable Investing

Personal Finance

Retirement

For Advisors

Alternative Investments

Media

Podcasts

Free Email Newsletters

Morningstar Magazine

Videos

Investing Definitions

Just For Investors

Morningstar Investor

Morningstar Investor Newsletters

Legacy Portfolio Manager

Home

Stocks

Boston Scientific Corp Boston Scientific Corp BSX

Morningstar Rating

Unlock Stock XNYS Rating as of Mar 6, 2024 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating Performance Dividends Ownership Executive $67.42 +0.40

(0.60%)

View Full Chart

As of Mar 7, 2024 12:00am Delayed Price Closed

Unlock our analysis with Morningstar Investor

Start Free Trial Company Report

View Archive

Boston Scientific Earnings: All Eyes Are on Farapulse to Drive Growth in 2024

Debbie Wang Jan 31, 2024

Narrow-moat Boston Scientific posted impressive fourth-quarter results that continued the strength seen in earlier quarters and generally met our expectations. As a result, we're holding steady on our fair value estimate. Quarterly operational revenue growth of 13% exceeded our estimates slightly, while better-than-expected gross margin in 2023 was offset by higher-than-expected spending on sales and marketing. Nevertheless, Boston remains in a strong position to grow faster than the medtech market again in 2024 thanks to U.S. rollout of Farapulse (pulsed field ablation, or PFA) for atrial fibrillation and continued adoption of Watchman FLX.

Read Full Report

Price vs Fair Value

View History

BSX is trading at a 23% premium.

Price

$67.42 Mar 6, 2024

Fair Value

$56.00 Aug 28, 2023

Uncertainty

Medium

1-Star Price $64.125-Star Price $42.70Economic Moat JpvcmykCapital Allocation Fhwfmgd Bulls Say, Bears Say Bulls Boston remains one of the top players when it comes to intellectual property in the medical technology arena, which bodes well for its ability to innovate enough to keep up with rivals. Bears Boston's coronary stent business is less moaty than its cardiac rhythm management segment.

Show More

Is it the right time to buy, sell, or hold?

Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BSX is a good fit for your portfolio.

Get 7 Days Free News

View All

Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon PR Newswire Mar 1, 2024 11:55am Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes PR Newswire Feb 27, 2024 9:15pm Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes PR Newswire Feb 23, 2024 2:27am Boston Scientific: Meeting Disabilities With Inclusion Accesswire Feb 14, 2024 1:15pm Boston Scientific: Honoring Our Indigenous Community - Past, Present and Future Accesswire Feb 7, 2024 1:45pm Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference PR Newswire Feb 5, 2024 1:00pm Boston Scientific: Sparking Social Change Through Volunteering Accesswire Feb 2, 2024 1:15pm Medical-device makers' stocks jump as procedures keep going strong MarketWatch Jan 31, 2024 5:48pm Trading Information Previous Close Price $67.02 Day Range $66.84–67.44 52-Week Range $46.20–67.67 Bid/Ask $67.15

/

$68.63 Market Cap $98.91 Bil Volume/Avg 6.4 Mil

/

6.2 Mil Key Statistics Price/Earnings (Normalized) 32.89Price/Sales 6.93Dividend Yield (Trailing) —Dividend Yield (Forward) —Total Yield — Company Profile Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Show More

Sector HealthcareIndustry Medical DevicesStock Style Box Large GrowthTotal Number of Employees 48,000Website https://www.bostonscientific.com Competitors Abbott Laboratories

ABT

Edwards Lifesciences Corp

EW

Medtronic PLC

MDT

Johnson & Johnson

JNJ

Valuation View More

Metric

BSX

ABT

EW

Price/Earnings (Normalized) 32.8926.8835.19Price/Book Value 5.135.367.98Price/Sales 6.935.208.96Price/Cash Flow 30.1421.4437.85 Price/Earnings

BSX

ABT

EW

Financial Strength

Metric

BSX

ABT

EW

Quick Ratio 0.631.162.08Current Ratio 1.321.643.38Interest Coverage 8.4110.8687.98 Quick Ratio

BSX

ABT

EW

Profitability

Metric

BSX

ABT

EW

Return on Assets (Normalized) 8.92%10.63%17.13%Return on Equity (Normalized) 16.33%20.87%24.32%Return on Invested Capital (Normalized) 11.43%14.81%21.12% Return on Assets

BSX

ABT

EW

See how this stock stacks up to its competitors with Morningstar Investor

Start Free Trial Medical Devices Industry Comparables

Screen in Investor

Ticker

Name

Morningstar Rating for Stocks

Economic Moat

Market Cap

ABT

Abbott Laboratories

Zcblgjf$207.1 Bil

SYK

Stryker Corp

Fzhf$135.0 Bil

MDT

Medtronic PLC

Qbh$113.6 Bil

EW

Edwards Lifesciences Corp

Tfqkc$53.1 Bil

DXCM

DexCom Inc

Qvfqf$51.6 Bil

ZBH

Zimmer Biomet Holdings Inc

Hgs$25.8 Bil

ALGN

Align Technology Inc

Bvwpwjb$22.8 Bil

PHG

Koninklijke Philips NV ADR

Wfsypr$18.5 Bil

SNN

Smith & Nephew PLC ADR

Zqqzb$12.0 Bil

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Read More

Transparency is how we protect the integrity of our work and keep

empowering investors to achieve their goals and dreams. And we have

unwavering standards for how we keep that integrity intact, from our

research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals

and individual investors. These products and services are usually sold through

license agreements or subscriptions. Our investment management business generates

asset-based fees, which are calculated as a percentage of assets under management.

We also sell both admissions and sponsorship packages for our investment conferences

and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to: Verify your identity, personalize the content you receive, or create and administer your account. Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.Gear advertisements and other marketing efforts towards your interests. To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of

empowering investor success. We provide a platform for our authors to report on

investments fairly, accurately, and from the investor’s point of view. We also

respect individual opinions––they represent the unvarnished thinking of our people

and exacting analysis of our research processes. Our authors can publish views that

we may or may not agree with, but they show their work, distinguish facts from

opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation

between our sales teams and authors to remove any pressure or influence on our analyses

and research.

Read our editorial policy to learn more about our process. Site Index What We Do All Products & Services Our Signature Methodologies Morningstar Investment Conference Company About Us Careers Diversity, Equity, & Inclusion Corporate Sustainability Newsroom Investor Relations Get Help Advertising Opportunities Feedback Reprints Global Contacts Affiliate Program

United States

© Copyright 2024 Morningstar, Inc. All rights reserved.

Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.

Terms and Conditions Privacy Center Disclosures Member User Agreement Corrections Do Not Sell or Share My Personal Information Accessibility

marketwatch.com

etwatch.comPlease enable JS and disable any ad blocker

Attention Required! | Cloudflare

Attention Required! | Cloudflare

Please enable cookies.

Sorry, you have been blocked

You are unable to access investing.com

Why have I been blocked?

This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.

What can I do to resolve this?

You can email the site owner to let them know you were blocked. Please include what you were doing when this page came up and the Cloudflare Ray ID found at the bottom of this page.

Cloudflare Ray ID: 8609950aae490eb8

Your IP:

Click to reveal

49.157.13.121

Performance & security by Cloudflare

波士顿科学 (BSX)_个股概要_股票价格_行情走势图_富途牛牛

波士顿科学 (BSX)_个股概要_股票价格_行情走势图_富途牛牛 个人服务 企业服务 简 English 繁體中文 简体中文 股票报价 股票 期权 期货 外汇 投资工具 选股器 热力图 财报日历 机构追踪 主题投资 资讯 要闻 24/7 财经日历 专题 视频 牛牛圈 推荐 话题广场 课堂 富途尊享服务 投资课程 词条百科 财报预测 投资讲座 帮助中心 关于 注册/登入 立即开户 暂无匹配内容 请检查网络设置后重试 刷新加载中富途热股热门资讯历史记录行情全部>资讯全部>帮助全部> 简体中文 浅色 深色 返回 股票报价 股票 期权 期货 外汇 投资工具 热力图 财报日历 机构追踪 主题投资 资讯 要闻 24/7 财经日历 专题 视频 牛牛圈 推荐 课堂 富途尊享服务 投资课程 词条百科 财报预测 投资讲座 帮助中心 关于 English 繁體中文 简体中文 深色 浅色 自选选股器热力图机构追踪美股市场个股详情

BSX 波士顿科学

添加自选

67.420

+0.400+0.60%收盘价 03/06 16:00 美东989.12亿总市值63.01市盈率TTM67.435最高价66.850最低价640.10万股成交量67.100今开67.020昨收4.30亿成交额0.44%换手率63.01市盈率(静)14.67亿总股本67.67352周最高5.13市净率985.39亿流通值46.21052周最低--股息TTM14.62亿流通股67.673历史最高--股息率TTM0.87%振幅4.790历史最低67.176平均价1股每手概览期权财务分析公司资讯评论盘前分时

盘前分时

盘中分时

盘后分时

全部分时

5日

日K

周K

月K

季K

年K

暂无内容成分股代码股票名称最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业暂无数据资金分布单位: --资金流向实时日周月暂无数据暂无数据

新闻

分析师看好顶级医疗保健股:维京疗法(VKTX)、波士顿科学(BSX)TipRanks11分钟前随着波士顿科学重申在24年上半年收盘,Axonics走高Seeking Alpha03:15派珀·桑德勒维持对波士顿科学(BSX)的买入评级TipRanks03/06 08:35到2030年,全球除颤器市场将达到208.4亿美元:全球行业分析以美敦力、波士顿科学和飞利浦医疗等主要参与者的概况为特色Yahoo Finance03/06 12:01根据美国证券交易委员会最近的一份文件,《波士顿科学内幕》出售了价值463,322美元的股票人力资源执行副总裁温迪·卡拉瑟斯于2024年3月1日以463,322美元的价格出售了波士顿科学(BSX)的6,983股股票。在向美国证券交易委员会提交表格4之后,卡鲁瑟斯继续提交表格MT Newswires03/05 11:14波士顿科学公司AGEN球囊导管获批,助力冠心病患者抗击再狭窄(医药健闻2024年3月5日讯)波士顿科学公司宣布旗下AGENT药物涂层球囊导管(DCB)已获得美国食品药品监督管理局(FDA)的批准,用于治疗冠状动脉疾病患者的支架内再狭窄(ISR)。ISR是指已植入支架的血管被斑块或疤痕组织阻塞或变窄的情况。 AGENT药物涂层球囊导管*继2021年被FDA授予"突破性医疗器械"认定后,该批准得到了多中心、前瞻性、随机对照AGENT DCB研究的阳性美通社03/05 12:17

分析

分析师评级暂无数据目标价预测暂无数据

热议

美股

美股

港股

加拿大

日股

澳股

新加坡

马来股

沪深

美股

综合热度

综合热度

交易热度

搜索热度

资讯热度

综合热度

股票代码

最新价

涨跌幅

关于我们 认识富途 投资者关系 加入富途 站点服务 交易費用 帮助中心 交易工具 协议声明 免责声明 服务条款 隐私声明 客户服务专线 +852 2523 3588 交易日:全天24小时 非交易日:09:30 - 21:30 1对1开户服务 WhatsApp +852 3001 5885 媒体查询:media@futuhk.com 商务合作:BD@futuhk.com 办公地址 香港金钟金钟道 95 号统一中心 13 楼 C1-2 室 营业时间:9:00am-6:00pm (星期一至五) 富途实体店 九龙尖沙咀弥敦道96号地下 (尖沙咀港铁站B1出口右行, TheONE对面) 营业时间:10:00am-10:00pm © 2024 FUTU. 反馈建议 信息安全漏洞反馈 投资者关系 富途牛牛服务协议 隐私政策 富途证券 富途安逸 友情链接 粤公网安备 44030502008587号 粤ICP备17008904号-3© 2024 FUTU

波士顿科学国际有限公司_百度百科

学国际有限公司_百度百科 网页新闻贴吧知道网盘图片视频地图文库资讯采购百科百度首页登录注册进入词条全站搜索帮助首页秒懂百科特色百科知识专题加入百科百科团队权威合作下载百科APP个人中心收藏查看我的收藏0有用+10波士顿科学国际有限公司播报讨论上传视频医疗器械的研发、生产和销售的跨国公司波士顿科学国际有限公司(纽约股市交易代码:BSX)是专注于微创伤介入医疗器械的研发、生产和销售的跨国公司。公司名称波士顿科学国际有限公司外文名Boston Scientifi C Corporation成立时间1979年总部地点美国麻省纳提克市经营范围医疗器械公司类型跨国企业员工数2.3 万人目录1企业简介2波士顿科学在中国3在华战略4公司地址5社会公益企业简介播报编辑全球约有23,000名员工,拥有超过13,000种产品,通过对涉及众多医学领域的产品创公司logo新、技术和服务上的广泛而深入的研究投入而推动了微创伤事业的发展。公司产品不断帮助医生和医药专家在提高病人生活质量方面提供了一种有别于外科手术而非常有效的新的治疗方式。波士顿科学在中国播报编辑1997年波士顿科学在中国成立了波士顿科学国际医疗贸易(上海)有限公司,从一个不到10名员工的代表处发展至今,在北京、上海、沈阳和广州建立了四个办事处。在中国,目前有近200名员工为我们的客户提供最优质的服务。2003年4月,波士顿科学国际医疗贸易(上海)有限公司成为行业内第一家开始采用直接面对医院销售的公司,此举成为中国医疗器械行业的里程碑。2023年10月9日,波士顿科学公司宣布,将在上海设立中国区首个生产制造基地。 [2]在华战略播报编辑为了更加务实地满足中国市场的需求,波士顿科学2014年启动了其在中国的首个企业战略—“创新冲击波计划”,旨在大力支持中国医疗健康领域的有效创新。“创新冲击波”计划秉承波士顿科学“为生命创新”的企业核心理念,从“创造生命奇迹”、“提升医疗效率”、“鼓励行业突破”三个层面传递、延续并持续创造“有效创新”的核心价值。这一举措进一步印证了波士顿科学成为中国医疗健康行业创新战略伙伴的坚定承诺。 [1]2006年通过对佳腾公司的并购,增加了心率调节管理业务部。公司地址播报编辑公司总部:麻省纳提克市 区域总部:巴黎、东京、新加坡社会公益播报编辑2023年12月20日,波士顿科学宣布捐款100万元驰援甘肃地震灾区,用于救灾物资采购、受灾群众生活安置和灾后重建等工作。 [3]新手上路成长任务编辑入门编辑规则本人编辑我有疑问内容质疑在线客服官方贴吧意见反馈投诉建议举报不良信息未通过词条申诉投诉侵权信息封禁查询与解封©2024 Baidu 使用百度前必读 | 百科协议 | 隐私政策 | 百度百科合作平台 | 京ICP证030173号 京公网安备110000020000

首頁 | BSX品牌線上購物 | 潮牌-潮流男裝/潮流女裝推薦

首頁 | BSX品牌線上購物 | 潮牌-潮流男裝/潮流女裝推薦

請閱讀我們的私隱聲明,瞭解我們如何處理您的個人資料。

關閉

臺灣 | NTD

購物車0

登入

會員註冊

BSX首頁

以下商品成功加入購物車

 件

查看購物車

結帳

服務條款

會員權益

購物操作說明

退貨申請

洗滌貼心小提醒

常見問題

關於佐丹奴

公司介紹

門市資訊

人才招募

性騷擾防治公告

聯絡我們

客服信箱

  

訂閱電子報

--

Giordano @Mobile | 

佐丹奴投資者關係 | 

佐丹奴香港官方網站 | 

BSX | 

giordano ladies | 

Complete List of Global E-Shop | 

香港商捷時海外貿易有限公司台灣分公司 台灣台北市中山區建國北路二段196號10樓